Lamotrigine is not a typical cause of tardive dyskinesia (TD), and the risk is considered rare. Unlike antipsychotic medications, which are the primary drivers of TD, lamotrigine does not block dopamine receptors, the mechanism most strongly linked to this condition. That said, a small number of cases have been reported, and the FDA prescribing information does list dyskinesia as an infrequent side effect.
Why TD Risk Is Low With Lamotrigine
Tardive dyskinesia is most commonly caused by medications that block dopamine D2 receptors in the brain. Antipsychotics, both older and newer generations, are the classic culprits because dopamine receptor blockade is central to how they work. Lamotrigine operates through a completely different mechanism. It primarily stabilizes electrical activity in the brain by blocking sodium channels and reducing the release of the excitatory brain chemical glutamate.
According to FDA receptor binding data, lamotrigine does not have meaningful affinity for dopamine D1 or D2 receptors. Its binding activity at those receptors is essentially negligible (IC50 greater than 100 µM, which in pharmacology terms means it takes an extremely high concentration to have any effect at all). This puts lamotrigine in a fundamentally different category from the drugs that routinely cause TD.
What the Clinical Evidence Shows
Despite the low theoretical risk, lamotrigine has been linked to TD in rare instances. A review published in the Ochsner Journal noted that both carbamazepine and lamotrigine are associated with TD, though it emphasized the incidence is rare. These are not large-scale findings but rather isolated case reports, which is the weakest level of evidence for a drug-side effect connection. It remains unclear whether lamotrigine directly caused TD in these cases or whether other factors, such as concurrent medications, contributed.
The FDA prescribing information for lamotrigine adds some nuance. In clinical trials across all uses, dyskinesia (involuntary movement, a broader category than TD specifically) was listed as an infrequent adverse reaction, meaning it occurred in somewhere between 1 in 100 and 1 in 1,000 patients. Extrapyramidal syndrome, a group of movement disorders that includes TD, was listed as rare, occurring in fewer than 1 in 1,000 patients. These categories include all forms of involuntary movement, not just the persistent kind that defines tardive dyskinesia.
Tremor vs. Tardive Dyskinesia
If you’re taking lamotrigine and noticing involuntary movements, it’s worth understanding what TD actually looks like versus other, more common side effects. Tremor, a rhythmic shaking typically in the hands, is a relatively well-known side effect of several mood stabilizers and anticonvulsants, including lamotrigine. Tremor is generally dose-related and tends to improve if the dose is lowered or the medication is stopped.
Tardive dyskinesia is different. It involves repetitive, purposeless movements, most often in the face: lip smacking, tongue protrusion, chewing motions, or grimacing. It can also affect the limbs and trunk. The hallmark of TD is that it develops after prolonged use of a medication (weeks to years) and can persist even after the drug is discontinued. If you’re experiencing a fine hand tremor, that is almost certainly not TD. If you’re noticing unusual facial or mouth movements that you can’t control, that warrants a conversation with your prescriber regardless of what medication you’re taking.
The Bigger Picture for People on Multiple Medications
Many people taking lamotrigine for bipolar disorder are also taking or have previously taken antipsychotic medications, which carry a much higher TD risk. In the United States, roughly 20 to 30 percent of people on long-term antipsychotic therapy develop some degree of TD. When someone on both an antipsychotic and lamotrigine develops involuntary movements, the antipsychotic is far more likely to be the cause.
This matters because it can be easy to attribute a new symptom to whatever medication was added most recently, even when the actual risk comes from a drug you’ve been taking longer. If you develop movement symptoms while on a combination of medications, the clinical picture is rarely as simple as pointing to one drug. Your prescriber will consider all of your medications, how long you’ve been on each, dosage changes, and your individual risk factors, which include older age, female sex, and a history of mood disorders.
How Lamotrigine Compares to Other Mood Stabilizers
Among medications used for bipolar disorder and seizure prevention, lamotrigine’s TD risk is similar to carbamazepine: present in case reports but rare enough that it isn’t a routine clinical concern. Lithium and valproate (the other major mood stabilizers) have their own movement-related side effects, primarily tremor, but are not strongly associated with TD either. The mood stabilizer class as a whole carries far less TD risk than antipsychotics. If you were prescribed lamotrigine specifically to avoid an antipsychotic, your TD risk is substantially lower on that regimen.
For most people, lamotrigine’s well-known side effects (rash, headache, dizziness, nausea, and insomnia) are far more relevant to daily life than the remote possibility of TD. The serious rash risk, particularly in the first few months, is generally the safety issue that gets the most clinical attention with this drug, and for good reason.